← All trials
NCT00213018
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 1999
- Primary completion
- —
- Completion date
- Jan 1, 2002
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Population CouncilLead sponsor
- Population CouncilOverall official - principal investigator
- FHI 360Collaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Medical Research Council, South AfricaCollaborator
- University of Cape TownCollaborator
- University of LimpopoCollaborator
- Bill and Melinda Gates FoundationCollaborator
- United States Agency for International DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.